Precigen (PGEN) Other Non-Current Assets (2012 - 2026)
Precigen's (PGEN) quarterly Other Non-Current Assets came in at $782000.0 in Q1 2026, up 83.14% year-on-year from $427000.0 in Q1 2025, and down 13.88% on a QoQ basis from $908000.0 in Q4 2025.
Precigen (PGEN) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Other Non-Current Assets data on file, last reported at $782000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 83.14% year-over-year to $782000.0 in Q1 2026; TTM through Mar 2026 was $782000.0, a 83.14% increase from a year earlier, with the FY2025 full-year figure at $908000.0, up 144.74% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $782000.0, down from $908000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for PGEN reached as high as $44.3 million in Q2 2022 and fell as low as $371000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $3.5 million across 5 years, with a median of $774500.0 in 2023.
- Across the five-year window, Other Non-Current Assets soared 402990.91% in 2022 and tumbled 97.86% in 2023, its largest moves.
- Year by year, Other Non-Current Assets stood at $1.0 million in 2022, then slipped by 25.17% to $767000.0 in 2023, then plunged by 51.63% to $371000.0 in 2024, then jumped by 144.74% to $908000.0 in 2025, then fell by 13.88% to $782000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $782000.0 in Q1 2026, $908000.0 in Q4 2025, and $753000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn | 782,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 782,000.00 |
| Dec 31, 2025 | 908,000.00 |
| Sep 30, 2025 | 753,000.00 |
| Jun 30, 2025 | 590,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 371,000.00 |
| Sep 30, 2024 | 425,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Dec 31, 2023 | 767,000.00 |
| Sep 30, 2023 | 797,000.00 |
| Jun 30, 2023 | 949,000.00 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Jun 30, 2022 | 44.34 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 936,000.00 |
| Jun 30, 2021 | 11,000.00 |
| Mar 31, 2021 | 1.43 Mn |
| Dec 31, 2020 | 1.60 Mn |